logo
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
EN 简
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • Autologous CAR-T
      • Allogeneic CAR-T
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us

Newsroom

  • Home -
  • Newsroom -
31
Jan 2023
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
Jan 31, 2023
20
Jan 2023
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
Jan 20, 2023
16
Jan 2023
CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China
Jan 16, 2023
28
Dec 2022
Results of a Collaborative Research on CAR T Technology between CARsgen and Shanghai Cancer Institute Published on Molecular Therapy
Dec 28, 2022
12
Dec 2022
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
Dec 12, 2022
31
Oct 2022
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
Oct 31, 2022
18
Oct 2022
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
Oct 18, 2022
21
Sep 2022
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit
Sep 21, 2022
02
Sep 2022
CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina
Sep 02, 2022
24
Aug 2022
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
Aug 24, 2022
  • 1
  • ...
  • 4
  • 5
  • 6
  • ...
  • 9
Wechat
qr
Linkedin
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
Privacy Policy Terms of Use Developed by Euroland IR
Copyright ©2021-2025 CARsgen Therapeutics Holdings Limited